Phaseline

Targets › NAD1

NAD1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Gastroenterology; next expected readout Dec 2027.

Open in Phaseline: the race on NAD1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauNicotinamide (NAM)
NAD+ precursor; promotes NAD+ biosynthesis and may support cellular metabolism and anti-in
PARP1, NAD1, NAMPTPhase 2Fatty LiverDec 2027

Conditions

Fatty Liver (1)

Modalities

small molecule (1)

Companies

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1)

Related targets

PARP1 (1) NAMPT (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.